Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | CRHBP | P24387 | 2/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287572 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL13325330 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL1309528 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL8772859 | 0.83 | ALDH1A1 (0.58) | SMN1; SMN2GAAALDH1A1USP2KMT2A | |
| SCHEMBL10341394 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2GAAALDH1A1LMNAUSP2 | |
| SCHEMBL7978023 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL11168013 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL10452572 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL17393894 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2GAACRHBPCRHR2ALDH1A1 | |
| SCHEMBL21132821 | 0.77 | NOS1 (0.45) | SMN1; SMN2ALDH1A1LMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149474-A1 | GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | claimed |
| US-9896433-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896433-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20150376165-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-7812026-B2 | Imidazole derivatives having a positive allosteric GABAB receptor modulator effect and methods of use | ASTRAZENECA AB (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7745474-B2 | tert-butyl 4-{[(4-chlorophenyl)carbonothioyl]amino}-2-(dimethylamino)-1-phenyl-1H-imidazole-5-carboxylate, having a positive allosteric GABA receptor modulator effect, used optionally in combination with a GABA receptor agonist; gastroesophageal reflux; irritable bowel syndrome; dyspepsia | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20090149474-A1 | GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| US-20090005428-A1 | Imidazole Derivatives for the Treatment of Gastrointestinal Disorders | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1968947-A1 | GABA-B RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1966154-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073298-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073300-A1 | GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1761531-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001750-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | SMN1; SMN2 1857/4885GAA 803/4885CRHBP 1209/4885 |
| US-20150376165-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | SMN1; SMN2 2999/4885GAA 78/4885CRHBP 4146/4885 |
| US-20090149474-A1 | GABA-B RECEPTOR MODULATORS | GABRB1, GABBR2, GABRB2 | SMN1; SMN2 1985/4885GAA 909/4885CRHBP 764/4885 |
| US-20090005428-A1 | Imidazole Derivatives for the Treatment of Gastrointestinal Disorders | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1693/4885GAA 765/4885CRHBP 1261/4885 |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HAVCR2, UGT1A1, UGT1A3 | SMN1; SMN2 3483/4885GAA 330/4885CRHBP 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.